Oculis Raises CHF20M To Advance Topical DME Therapy And Turn Swiss
Icelandic clinical stage biotech Oculis closes CHF20M ($20.3m) series B financing to advance development of its Phase IIb topical DME drug candidate, relocate to Switzerland and beef up its management team.
You may also be interested in...
BioNTech's $270m Series A round was the biggest start-up financing in January, but sizeable rounds also were raised by Centrexion ($67m), Eureka ($60m) and Pandion ($58m).
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.